Trastuzumab and Breast Cancer. Are we just Beyond the Prologue of a Fascinating Story?
Open Access
- 1 October 2005
- journal article
- editorial
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 28 (11), 547-549
- https://doi.org/10.1159/000088849
Abstract
EditorialSCOPUS: ed.jinfo:eu-repo/semantics/publisheKeywords
This publication has 18 references indexed in Scilit:
- Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With PaclitaxelJournal of Clinical Oncology, 2003
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Humanization of an anti-p185HER2 antibody for human cancer therapy.Proceedings of the National Academy of Sciences, 1992
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen.Proceedings of the National Academy of Sciences, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.Proceedings of the National Academy of Sciences, 1985
- Amplification of a Novel v- erb B-Related Gene in a Human Mammary CarcinomaScience, 1985
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature, 1984